Nucleic Acid Therapeutics for Treatment of Respiratory Diseases
Non Visible
?
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Eleven Therapeutics is focused on developing the next generation of RNAi therapeutics by combining artificial intelligence (AI), massively parallel functional assays, and combinatorial chemistry.
The companys flagship invention features a new single-chassis, small interfering RNA (SCSI-RNA) modality. The fully programmable molecule is rationally designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest.
Eleven Therapeutics is currently focusing its development pipeline on siRNA treatments for a range of respiratory diseases.